全文获取类型
收费全文 | 138421篇 |
免费 | 9761篇 |
国内免费 | 298篇 |
专业分类
耳鼻咽喉 | 1707篇 |
儿科学 | 3800篇 |
妇产科学 | 3022篇 |
基础医学 | 20491篇 |
口腔科学 | 3550篇 |
临床医学 | 13264篇 |
内科学 | 28266篇 |
皮肤病学 | 2175篇 |
神经病学 | 12779篇 |
特种医学 | 5638篇 |
外国民族医学 | 55篇 |
外科学 | 19562篇 |
综合类 | 1034篇 |
现状与发展 | 1篇 |
一般理论 | 169篇 |
预防医学 | 12165篇 |
眼科学 | 2370篇 |
药学 | 9203篇 |
中国医学 | 235篇 |
肿瘤学 | 8994篇 |
出版年
2023年 | 550篇 |
2021年 | 2429篇 |
2020年 | 1729篇 |
2019年 | 2582篇 |
2018年 | 3084篇 |
2017年 | 2306篇 |
2016年 | 2585篇 |
2015年 | 2948篇 |
2014年 | 3999篇 |
2013年 | 5818篇 |
2012年 | 8223篇 |
2011年 | 8398篇 |
2010年 | 5056篇 |
2009年 | 4659篇 |
2008年 | 7329篇 |
2007年 | 7474篇 |
2006年 | 7248篇 |
2005年 | 6997篇 |
2004年 | 6678篇 |
2003年 | 6128篇 |
2002年 | 5762篇 |
2001年 | 3762篇 |
2000年 | 3738篇 |
1999年 | 3410篇 |
1998年 | 1493篇 |
1997年 | 1262篇 |
1996年 | 1177篇 |
1995年 | 1173篇 |
1994年 | 1065篇 |
1993年 | 1073篇 |
1992年 | 2433篇 |
1991年 | 2306篇 |
1990年 | 2197篇 |
1989年 | 2121篇 |
1988年 | 1841篇 |
1987年 | 1729篇 |
1986年 | 1665篇 |
1985年 | 1540篇 |
1984年 | 1137篇 |
1983年 | 1003篇 |
1982年 | 695篇 |
1981年 | 654篇 |
1980年 | 551篇 |
1979年 | 937篇 |
1978年 | 555篇 |
1977年 | 532篇 |
1975年 | 546篇 |
1974年 | 584篇 |
1973年 | 526篇 |
1972年 | 526篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
3.
4.
5.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
6.
7.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
8.
Josupeit Jan Dadaczynski Kevin Quilling Eike 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(7-8):829-835
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Die Schule ist einer der wichtigsten Orte, an dem die Förderung der Gesundheit von Kindern und Jugendlichen ansetzen kann,... 相似文献
9.